On December 18, 2023, the Minister of Health announced the creation of the Canadian Drug Agency. According to the announcement, the Canadian Drug Agency (CDA) “will provide the dedicated leadership and coordination needed to make Canada's drug system more sustainable and better prepared for the future, helping Canadians achieve better health outcomes.” It will be built from the Canadian Agency for Drugs and Technologies in Health (CADTH), in partnership with provinces and territories. The CDA will build on CADTH’s mandate and functions, and will expand them, including improving appropriate prescribing and use of medications, and increasing pan-Canadian data collection and expanding access to drug and treatment data, including real-world evidence data.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and life sciences regulatory law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Canada’s Drug Agency releases updated Procedures for Reimbursement Reviews & new data on Health Technology Assessment timelines
On April 30, 2026, Canada’s Drug Agency (CDA) published updated Procedures for Reimbursement Reviews, following completion of a public consultation earlier this year. The updated procedures will be ef...Read More -
PMPRB releases May NEWSLetter and Meds Pipeline Monitor
On May 12, 2026, the Patented Medicine Prices Review Board (PMPRB) released its May NEWSLetter. The NEWSletter provides updates on the implementation of the new Guidelines for PMPRB Staff, the consult...Read More -
2026 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2026, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top storiesRead More
